SCHEMBL12424645

SCHEMBL12424645

COc1cc2c(O)cc3c(c2cc1OC)-c1ccccc1-c1ccccc1C31CC(C)(C)C(C)(C)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.35
EP300 Q09472 1/20 0.34
PDK2 Q15119 4/20 0.33
GAA P10253 2/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 4/20 0.31
MAPT P10636 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31
MEN1 O00255 3/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CYP1A2 P05177 2/20 0.30
ESR1 P03372 1/20 0.30
ESR2 Q92731 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP1A1 P04798 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12424702 0.93 PARP1 (0.35) PARP1EP300PDK2GAAHPGD
SCHEMBL24404156 0.88 PDK2 (0.35) PARP1EP300PDK2GAAHPGD
SCHEMBL12424610 0.85 EHMT2 (0.35) PARP1EP300PDK2GAAHPGD
SCHEMBL10292851 0.85 PDK2 (0.35) PARP1PDK2GAAHPGDKMT2A
SCHEMBL12424647 0.83 CNR2 (0.32) KMT2AMAPTTP53MEN1
SCHEMBL12424649 0.82 KMT2A (0.33) PARP1EP300PDK2GAAHPGD
SCHEMBL12424633 0.82 ESR1 (0.40) PARP1EP300PDK2GAAHPGD
SCHEMBL24799508 0.81 EHMT2 (0.36) PARP1EP300PDK2GAAHPGD
SCHEMBL25954033 0.81 PARP1 (0.33) PARP1EP300PDK2GAAHPGD
SCHEMBL15247954 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
EP-2055698-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100230649-A1 CHROMENE COMPOUND CCNT1, RB1, H1-0 PARP1 1524/4885EP300 1803/4885PDK2 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.